Impact of Thrombophilia Testing on Clinical Management: A Retrospective Cohort Study

Abstract

Thrombophilia management is based on the personal and family history of thrombosis. Current guidelines recommend performing thrombophilia testing only when the results will change clinical management. To investigate to what extent treatment recommendations changed following thrombophilia testing, clinical and laboratory data of 255 patients with and without venous thromboembolism who underwent thrombophilia screening were assessed retrospectively. A local score based on clinical indicators for thrombophilia was used to assess the pretest probability of thrombophilia. A total of 144 patients (57.6%) were found to have a clear thrombophilic phenotype, of which 78 were predicted to have definite thrombophilia and considered for indefinite anticoagulation; 66 were likely to have thrombophilia and were considered for indefinite or prolonged anticoagulation. Eighty-three (32.5%) could not be clearly classified and 28 (11%) were asymptomatic. A thrombophilic risk factor was diagnosed in 98 (38.4%) patients; this included 64 of 144 (44.5%) patients with a clear thrombophilic phenotype and 26 of 83 (31.3%) patients who could not be easily classified. Treatment recommendations changed in 57 of 255 (22%) patients following thrombophilia testing. Eight patients were switched from direct oral anticoagulants to vitamin K antagonists due to confirmed triple-positive antiphospholipid syndrome. In 49 patients, the anticoagulant dose was either increased (n = 3) or treatment was prolonged (n = 46) following diagnosis of high-risk thrombophilia. Clinically, assessing thrombophilia probability score before thrombophilia testing improves thrombophilia management recommendations.

Keywords

risk assessment - thrombophilia - anticoagulation therapy - thrombophilia testing

Data Sharing Statement

For original data, please contact [e-mail].

Authors' Contributions

H.L.M. and B.P. designed the research and co-wrote the manuscript; H.L.M., H.R., and B.P. collected and analyzed the data; H.R. performed statistical analysis; H.R. and J.M. reviewed and edited the manuscript; B.P. supervised study activities. All authors have read and agreed to the final version of the manuscript.

Publication History

Received: 24 July 2024

Accepted: 21 October 2024

Article published online:
10 December 2024

• References

• 1 Arachchillage DJ, Mackillop L, Chandratheva A, Motawani J, MacCallum P, Laffan M. Thrombophilia testing: a British Society for Haematology guideline. Br J Haematol 2022; 198 (03) 443-458
• 2 Connors JM. Thrombophilia testing and venous thrombosis. N Engl J Med 2017; 377 (12) 1177-1187
• 3 Knight JS, Branch DW, Ortel TL. Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. BMJ 2023; 380: e069717
• 4 Linnemann B, Beyer-Westendorf J, Espinola-Klein C, Mühlberg KS, Müller OJ, Klamroth R. Management of deep vein thrombosis: an update based on the Revised AWMF S2k Guideline. Hamostaseologie 2024; 44 (02) 97-110
• 5 Middeldorp S, Nieuwlaat R, Baumann Kreuziger L. et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv 2023; 7 (22) 7101-7138
• 6 Dicks AB, Moussallem E, Stanbro M, Walls J, Gandhi S, Gray BH. A comprehensive review of risk factors and thrombophilia evaluation in venous thromboembolism. J Clin Med 2024; 13 (02) 362
• 7 Moran J, Bauer KA. Managing thromboembolic risk in patients with hereditary and acquired thrombophilias. Blood 2020; 135 (05) 344-350
• 8 Becattini C, Cimini LA. Long term use of anticoagulant therapy for patients with pulmonary embolism. Expert Rev Hematol 2020; 13 (07) 709-718
• 9 Devreese KMJ, de Groot PG, de Laat B. et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost 2020; 18 (11) 2828-2839
• 10 Ong J, Bennett A. A review of laboratory considerations in thrombophilia testing. Pathology 2022; 54 (07) 835-841
• 11 Diavati S, Sagris M, Terentes-Printzios D, Vlachopoulos C. Anticoagulation treatment in venous thromboembolism: options and optimal duration. Curr Pharm Des 2022; 28 (04) 296-305
• 12 Fernandes CJ, Calderaro D, Piloto B, Hoette S, Jardim CVP, Souza R. Extended anticoagulation after venous thromboembolism: Should it be done?. Ther Adv Respir Dis 2019; 13: 1753466619878556
• 13 Bikdeli B, Zahedi Tajrishi F, Sadeghipour P. et al. Efficacy and safety considerations with dose-reduced direct oral anticoagulants: a review. JAMA Cardiol 2022; 7 (07) 747-759
• 14 Wang X, Ma Y, Hui X. et al. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis. Cochrane Database Syst Rev 2023; 4 (04) CD010956
• 15 Yamashita Y, Amano H, Morimoto T. et al; COMMAND VTE Registry Investigators. Risk factors of thrombotic recurrence and major bleeding in patients with intermediate-risk for recurrence of venous thromboembolism. J Thromb Thrombolysis 2022; 53 (01) 182-190
• 16 Linnemann B, Blank W, Doenst T. et al. Diagnostics and therapy of venous thrombosis and pulmonary embolism. The revised AWMF S2k guideline. Vasa 2023; 52 (S111): 1-146
• 17 Ortel TL, Neumann I, Ageno W. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4 (19) 4693-4738
• 18 Moser KA, Smock KJ. Direct oral anticoagulant (DOAC) interference in hemostasis assays. Hematology (Am Soc Hematol Educ Program) 2021; 2021 (01) 129-133
• 19 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
• 20 Happich D, Madlener K, Schwaab R, Hanfland P, Pötzsch B. Application of the TaqMan-PCR for genotyping of the prothrombin G20210A mutation and of the thermolabile methylenetetrahydrofolate reductase mutation. Thromb Haemost 2000; 84 (01) 144-145
• 21 Luderer R, Verheul A, Kortlandt W. Rapid detection of the factor V Leiden mutation by real-time PCR with TaqMan minor groove binder probes. Clin Chem 2004; 50 (04) 787-788
• 22 Pastori D, Menichelli D, Cammisotto V, Pignatelli P. Use of direct oral anticoagulants in patients with antiphospholipid syndrome: a systematic review and comparison of the international guidelines. Front Cardiovasc Med 2021; 8: 715878
• 23 Marlar RA, Gausman JN, Tsuda H, Rollins-Raval MA, Brinkman HJM. Recommendations for clinical laboratory testing for protein S deficiency: Communication from the SSC committee plasma coagulation inhibitors of the ISTH. J Thromb Haemost 2021; 19 (01) 68-74
• 24 Reda S, Rühl H, Witkowski J. et al. PC deficiency testing: thrombin-thrombomodulin as PC activator and aptamer-based enzyme capturing increase diagnostic accuracy. Front Cardiovasc Med 2021; 8: 755281
• 25 Van Cott EM, Orlando C, Moore GW, Cooper PC, Meijer P, Marlar R. Subcommittee on Plasma Coagulation Inhibitors. Recommendations for clinical laboratory testing for antithrombin deficiency; Communication from the SSC of the ISTH. J Thromb Haemost 2020; 18 (01) 17-22